Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cue Biopharma Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $2.954M Beat $2.396M Estimate

Author: Benzinga Newsdesk | August 12, 2025 03:33pm
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 55 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $2.954 million which beat the analyst consensus estimate of $2.396 million by 23.31 percent. This is a 11.14 percent increase over sales of $2.658 million the same period last year.

Posted In: CUE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist